Back to Search
Start Over
Inhaled nitric oxide (iNO) for preventing prematurity-related bronchopulmonary dysplasia (BPD): 7-year follow-up of the European Union Nitric Oxide (EUNO) trial.
- Source :
- Journal of Perinatal Medicine; Jan2021, Vol. 49 Issue 1, p104-110, 7p
- Publication Year :
- 2021
-
Abstract
- Most studies of inhaled nitric oxide (iNO) for prevention of bronchopulmonary dysplasia (BPD) in premature infants have focused on short-term mortality and morbidity. Our aim was to determine the long-term effects of iNO. A 7-year follow-up was undertaken of infants entered into a multicenter, double-blind, randomized, placebo-controlled trial of iNO for prevention of BPD in premature infants born between 24 and 28 weeks plus six days of gestation. At 7 years, survival and hospital admissions since the 2-year follow-up, home oxygen therapy in the past year, therapies used in the previous month and growth assessments were determined. Questionnaires were used to compare general health, well-being, and quality of life. A total of 305 children were assessed. No deaths were reported. Rates of hospitalization for respiratory problems (6.6 vs. 10.5%, iNO and placebo group, respectively) and use of respiratory medications (6.6 vs. 9.2%) were similar. Two patients who received iNO and one who received placebo had received home oxygen therapy. There were no significant differences in any questionnaire-documented health outcomes. iNO for prevention of BPD in very premature infants with respiratory distress did not result in long-term benefits or adverse long-term sequelae. In the light of current evidence, routine use of iNO cannot be recommended for prevention of BPD in preterm infants. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 03005577
- Volume :
- 49
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Journal of Perinatal Medicine
- Publication Type :
- Academic Journal
- Accession number :
- 148338601
- Full Text :
- https://doi.org/10.1515/jpm-2020-0164